Summarized by Masters of Longevity from Longevity Docs News.
A concise healthcare news article about the FDA clearing the first generic weekly combined hormone patch, explaining its clinical role and implications for menopausal treatment access.
Key Takeaways
- The FDA approved Zydus Pharmaceuticals' generic estradiol 0.045 mg and levonorgestrel 0.015 mg per day transdermal system as therapeutically equivalent to the brand.
- The approved indications match the reference: treatment of moderate to severe vasomotor symptoms and prevention of postmenopausal osteoporosis in women with an intact uterus.
- The FDA noted standard contraindications including breast cancer history, thromboembolic disorders, liver disease, and unexplained genital bleeding.
